You are here: Industry Insights > Novartis

News List

Novartis Launches Portfolio of Meds for COVID-19 Treatment contractpharma
July 17, 2020
Portfolio of 15 generic and OTC medicines from Sandoz will be sold at zero-profit to governments in eligible countries during the pandemic.
Novartis receives EC approval for Enerzair Breezhaler americanpharmaceuticalreview
July 16, 2020
Novartis announced the European Commission (EC) has approved Enerzair® Breezhaler® (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately ...
Novartis Receives Approval for Five Products from Japanese Ministry of Health americanpharmaceuticalreview
July 10, 2020
Novartis Pharma announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved five new treatment options for Japanese patients.
Novartis Receives Positive CHMP Opinion for New Xolair Indication americanpharmaceuticalreview
July 09, 2020
Novartis announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Xolair® (omalizumab) as an add-on therapy with intranasal corticosteroids (INC) ...
Novartis banks EC approval for Enerzair Breezhaler pharmatimes
July 08, 2020
The European Commission (EC) has approved Novartis' Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) for uncontrolled asthma.
Vectura Earns $5M Novartis Milestone for Enerzair Breezhaler contractpharma
July 08, 2020
Enerzair Breezhaler uses Vectura’s formulation IP, and is a first-in-class fixed-dose combination maintenance treatment for uncontrolled asthma.
Novartis Resolves Legacy FCPA Investigations americanpharmaceuticalreview
July 07, 2020
Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA) investigations into historical conduct by the Company and its subsidiaries.
Novartis agrees to pay $678m to settle kickback charges in US pharmaceutical-technology
July 03, 2020
Novartis Pharmaceuticals has agreed to pay $678m to settle claims that the company made payments of kickback to doctors who prescribed its medicines, as well as Medicare patients.
NICE does not recommend Novartis’ siponimod for secondary progressive MS europeanpharmaceuticalreview
June 30, 2020
NICE has decided to not recommend Mayzent (siponimod) for use on the NHS as a secondary progressive multiple sclerosis treatment because its clinical trial did not directly compare it to interferon beta-1b.
NICE rejects Novartis' Mayzent for secondary progressive MS pharmatimes
June 29, 2020
NICE has turned down NHS funding in preliminary guidelines for use of Novatis' Mayzent (siponimod) as a treatment for secondary progressive multiple sclerosis (SPMS) with evidence of active disease.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page